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Purpose: Along with their cholesterol-lowering effect, statins have shown a wide range of 
pleiotropic effects potentially beneficial to neurodegenerative diseases. However, such effects 
are extremely elusive via the conventional oral administration. The purpose of the present study 
was to prepare and characterize the physicochemical properties and the in vivo biodistribution of 
simvastatin-loaded lecithin/chitosan nanoparticles (SVT-LCNs) suitable for nasal administration 
in view of an improved delivery of the statins to the brain.
Materials and methods: Chitosan, lecithin, and different oil excipients were used to prepare 
nanocapsules loaded with simvastatin. Particle size distribution, surface charge, structure, 
simvastatin loading and release, and interaction with mucus of nanoparticles were determined. 
The nanoparticle nasal toxicity was evaluated in vitro using RPMI 2651 nasal cell lines. 
Finally, in vivo biodistribution was assessed by gamma scintigraphy via Tc99m labeling of 
the particles.
Results: Among the different types of nanoparticles produced, the SVT-LCN_MaiLab showed 
the most ideal physicochemical characteristics, with small diameter (200 nm), positive surface 
charge (+48 mV) and high encapsulation efficiency (EE; 98%). Size distribution was further 
confirmed by nanoparticle tracking analysis and electron microscopy. The particles showed a 
relatively fast release of simvastatin in vitro (35.6%±4.2% in 6 hours) in simulated nasal fluid. 
Blank nanoparticles did not show cytotoxicity, evidencing that the formulation is safe for nasal 
administration, while cytotoxicity of simvastatin-loaded nanoparticles (IC
50
) was found to be 
three times lower than the drug solution (9.92 vs 3.50 µM). In rats, a significantly higher radio-
activity was evidenced in the brain after nasal delivery of simvastatin-loaded nanoparticles in 
comparison to the administration of a similar dose of simvastatin suspension.
Conclusion: The SVT-LCNs developed presented some of the most desirable characteristics 
for mucosal delivery, that is, small particle size, positive surface charge, long-term stability, 
high EE, and mucoadhesion. In addition, they displayed two exciting features: First was their 
biodegradability by enzymes present in the mucus layer, such as lysozyme. This indicates a new 
Trojan-horse strategy which may enhance drug release in the proximity of the nasal mucosa. 
Second was their ability to enhance the nose-to-brain transport as evidenced by preliminary 
gamma scintigraphy studies.
Keywords: nose-to-brain, simvastatin, nanoparticles, neurodegenerative diseases, gamma 
scintigraphy, small-angle X-ray scattering (SAXS), lysozyme, biodegradable nanoparticles
Introduction
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
or statins, are arguably among the biggest advances in cardiovascular care in the 
20th century. Statins reduce cholesterol serum levels by reversibly inhibiting HMG-
CoA reductase, an essential enzyme in cholesterol biosynthesis, reducing the risk of 
serious cardiovascular events.1,2 Along with their lipid-lowering effects, statins have 
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been credited for a range of outcomes or “pleiotropic effects”.3 
The mechanisms by which pleiotropic outcomes occur are 
diverse and still not fully elucidated. Many of those effects are 
attributed to the inhibition of isoprenoid intermediates, that is, 
farnesyl pyrophosphate and geranylgeranyl pyrophosphate, 
and their downstream effects on intracellular signaling 
proteins Ras, Rho, and Rac.4 Pleiotropic effects of statins 
include anti-inflammatory, antioxidant, immunomodulatory, 
and antithrombotic actions as well as the ability to stabilize 
atherosclerotic plaques and inhibit the proliferation of 
vascular smooth muscle.5–7 Because of these pleiotropic 
effects, it is now believed that statins could be more widely 
employed in other diseases, such as rheumatoid arthritis, 
COPD, cancer, and neurodegenerative disorders.8–11
In the case of Alzheimer’s disease, clinical research evi-
denced that an increase in brain cholesterol levels directly 
upregulates the production of β-amyloid protein, the major 
protein involved in the formation of senile plaques in the 
brain of Alzheimer’s patients.12,13 Moreover, the most widely 
recognized risk factor of late-onset Alzheimer’s is the genetic 
variation in a transporter of cholesterol called apolipoprotein 
E ε4 which supposedly alters the brain cholesterol homeo-
stasis, leading to Alzheimer’s disease development.14,15 The 
inhibition of brain cholesterol synthesis has been shown to 
reduce β-amyloid accumulation, interfering with the pro-
duction of β-amyloid and its accumulation as extracellular 
plaques.16,17 These works suggest that the effects of statins 
in lowering the cholesterol levels may have a beneficial 
role on the pathogenesis of Alzheimer’s disease. It has also 
been postulated that statin pleiotropic effects could provide 
further benefit to Alzheimer’s patients via modulation of 
the chronic inflammatory response, another key factor in 
neurodegenerative process.11 However, these effects of sta-
tins are only seen at high therapeutic concentrations at the 
target organ, and they are difficult to be observed when the 
conventional oral administration route is selected. In fact, 
statins undergo extensive first-pass metabolism, and their 
hydrophilic metabolites are prevented from crossing the 
blood–brain barrier (BBB), the principal biological barrier 
protecting the central nervous system (CNS).3 Despite the 
fact that statins are generally well tolerated, this drug class 
has been associated with some adverse events, in particular 
myopathy. This side effect can be severe and progress to 
rhabdomyolysis, to the point that cerivastatin was withdrawn 
from the market in 2001 as a consequence of 52 drug-related 
fatalities worldwide.18
In the last few decades, the nasal mucosa has been 
demonstrated to be a site for drug administration that could 
allow for fast and efficient absorption of drug molecules 
normally not suitable for oral administration.19 More recently, 
the intranasal route has been increasingly investigated to 
deliver drugs to the brain aimed at the treatment of specific 
brain diseases, including neurological diseases, such as 
Parkinson’s, schizophrenia, epilepsy, and Alzheimer’s.20 
Several research suggest that the “nose-to-brain” route is 
one of the most important developments of pharmaceutical 
research in brain treatment, including the following: i) the 
potential to avoid gastrointestinal (GI) and hepatic first-pass 
metabolism; ii) the possibility of delivering drugs not suitable 
for oral administration, such as peptides and proteins; and 
iii) most importantly, the transport of exogenous material 
directly from the nasal cavity to the brain, thus bypassing 
the BBB.21,22 It is known that the unique physiology of the 
olfactory region within the nasal cavity can provide a direct 
route of administration to the CNS, through the main innerva-
tion of the nasal cavity, that is, the olfactory and trigeminal 
nerves.23,24 However, drug delivery via the nose is also limited 
by a number of factors such as the administration volume, the 
barrier of the nasal epithelium, the nasal metabolic activity 
and the presence of a protective mucus layer. Additionally, 
the amount of drug administered nasally which has been 
shown to be transported directly from nose-to-brain is very 
low, normally 0.1%. Hence, the system is not currently 
used in clinical practice.25
The extent of the nose-to-brain drug absorption has been 
shown to be highly dependent on the drug formulation.26,27 
The strategy of administering drugs encapsulated in nanopar-
ticles via the olfactory epithelium could potentially improve 
the direct CNS delivery. Nanoparticles can improve nose-to-
brain drug delivery, since they are able to interact with the 
nasal epithelium enhancing the drug absorption, protect the 
encapsulated drug from biological/chemical degradation and 
avoid the drug transport to the extracellular space by efflux 
proteins, such as P-glycoprotein. This could potentially 
increase CNS availability of the drug. In addition, their 
small diameter potentially allows for transcellular transport 
of nanoparticles through olfactory neurones to the brain, 
via the various endocytic pathways of neuronal cells in the 
olfactory region.21
From a drug delivery perspective, polymeric nanoparticles 
have proven to perform statistically better in delivering model 
drugs into CNS, in enhancing their pharmacological activity 
and/or reducing side effects, when compared to traditional 
formulations of drugs, when administered intranasally.28,29 
Colloid nanoparticles, composed of polysaccharides, such 
as chitosan, and phospholipids, have been proposed recently 
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as a biocompatible, biodegradable, and safe delivery system 
for poorly soluble drugs in order to overcome biological 
barriers.30,31 Their chitosan surface layer in particular has the 
potential to facilitate nasal delivery, due to the polysaccharide 
mucoadhesive properties and its potential to increase epithe-
lial permeability by interaction with the junctional complexes 
between cells.32,33 In addition, this approach could potentially 
reduce classical statin side effects as nasal delivery allows 
dosage reduction and systemic exposure to the drug.
In the present study, a mucoadhesive formulation based 
on self-assembled lecithin/chitosan nanoparticles (LCNs) 
designed for intranasal administration was developed and 
optimized as a promising strategy for delivering simvastatin 
into the CNS. Desired features of this approach were high 
positive charge, small particle size and high drug content. 
In order to obtain these features, different oils were incor-
porated into LCNs in order to optimize the formulation. 
Physical and chemical stabilities were assessed along with 
drug release in simulated nasal fluid. Nanoparticle structure 
and interaction with mucus with and without lysozyme 
were investigated as well. The in vitro nasal toxicity of the 
nanoparticles alone or loaded with simvastatin was evalu-
ated in a human nasal cell line (RPMI 2651). Finally, a pre-
liminary gamma scintigraphy study of the biodistribution 
of simvastatin-loaded nanoparticles in vivo after intranasal 
instillation was carried out in rats.
Materials and methods
Materials
Chitosan (Chitoclear FG, deacetylation degree 95%, viscosity 
45 cP) was provided by Primex (Siglufjordur, Iceland) and 
used without further purification. Lecithin (Lipoid S45) 
was obtained from Lipoid AG (Ludwigshafen, Germany). 
Pharmaceutical-grade oils Maisine™ 35-1 (glycerol mono-
linoleate), Labrafac™ Lipophile WL 1349 (medium-chain 
triglycerides, European Pharmacopoeia), Capryol™ PGMC 
(propylene glycol monocaprylate type I, National Formulary 
[NF]), and Capryol™ 90 (propylene glycol monocaprylate 
type II, NF), were a kind gift of Gattefossé (Saint-Priest, 
France). Simvastatin USP 99%, mucin from porcine stomach 
(type III), human lysozyme and bovine serum albumin (BSA) 
were supplied by Sigma-Aldrich (St Louis, MO, USA).
Centrifugal filter devices (Vivaspin® 2; 30,000 molecular 
weight cut-off [MWCO] HY) were obtained from Sartorius 
(Göttingen, Germany). Dialysis tubing cellulose (14,000 
MWCO) was supplied by Sigma-Aldrich. Cell line RPMI 2650 
(CCL-30) was purchased from American Type Culture Col-
lection (ATCC) (Manassas, VA, USA). Minimum essential 
medium (MEM) and fetal bovine serum (FBS) were acquired 
from Thermo Fisher Scientific (Waltham, MA, USA). Cell 
culture inserts and other culture plastics were from Corning 
Incorporated (Corning, NY, USA). All other chemicals were 
of analytical grade. Ultrapure and degassed ultrapure water 
(Purelab Flex; ELGA-Veolia LabWater, Windsor Court, UK) 
was used in all experiments.
Methods
Preparation of simvastatin-loaded lcNs
Simvastatin-loaded (SVT) LCNs were prepared as reported 
previously with slight modifications. In summary, 4 mL of 
an ethanol solution containing soybean lecithin (100 mg), 
simvastatin (50 mg) and different types of oils (Maisine 
[Mai], Labrafac [Lab], Capryol PGMC [Cap
I
], and Capryol 
90 [Cap
II
]) in 1:1 binary combination (100+100 mg) was 
injected, at controlled flow rate (15 mL/min), into 50 mL 
of 0.01% (w/v) chitosan aqueous solution, under constant 
mechanical stirring at 15,000 rpm for 10 minutes (Ultraturrax 
TP 18/10 – 10N; IKA-Werke GmbH, Staufen, Germany). The 
0.01% chitosan aqueous solution was prepared from a 1% 
chitosan solution in 0.03 N HCl. Volume of organic phase 
and rate flow injection (15 mL/min) were controlled using a 
mechanical syringe pump coupled with a glass pipette (Model 
200; KD Scientific, Holliston, MA, USA). Finally, ethanol 
phase was evaporated from the prepared colloidal suspen-
sion using a rotary evaporator (Heidolph WB/VV 2000; 
Schwabach, Germany) at the temperature of 40°C. Batches of 
LCNs loaded with simvastatin, without oil (SVT-LCNs) and 
with different oils (SVT-LCN_MaiLab, SVT-LCN_MaiCap
I
, 
SVT-LCN_LabCap
I
, and SVT-LCN_Cap
I
Cap
II
), were pro-
duced in order to optimize the formulation for stability and 
simvastatin encapsulation. All batches were prepared in 
at least triplicate and stored at room temperature for up to 
3 months.
Physicochemical characterization of sVT-lcNs
Determination of nanoparticle size and surface charge
The particle size and polydispersity index (PDI) of all nano-
particles were determined by dynamic light scattering (DLS) 
using Malvern Zetasizer Nano ZSP (Malvern Instruments 
Ltd., Malvern, UK).
For DLS measurements, the colloidal nanoparticle sus-
pensions were diluted with distilled water filtered at 0.45 µm 
to avoid multiple scattering. The analysis was performed 
at 25°C and at a 90° scattering angle. Three measurements 
were performed for each sample, in triplicate (n=9± standard 
deviation [SD]).
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The surface charge of the nanoparticles was measured 
using phase analysis light scattering. The same samples were 
used for both size and zeta potential determination, with 
the same instrument. For each measurement, nanoparticles 
were diluted (1:3) with distilled water filtered at 0.45 µm 
to achieve a desired conductance (300 µS) without altering 
the surface charge properties of nanoparticles. Zeta potential 
values were presented as means of triplicate runs (six sub-
runs) per sample (n=9± SD).
Nanoparticle tracking analysis
In order to further confirm the particle size distribution and 
have an evaluation of particle concentration in suspension, 
a nanoparticles tracking analysis (NTA) experiment was 
conducted using NanoSight NS300 (Malvern Instruments 
Ltd.) equipped with a 480 nm laser light source, and a 20× 
magnification microscope was used to carry out the particle 
tracking analysis with a field of view of approximately 
100×80×10 µm. The built-in sCMOS camera was used to 
record videos, and the particle tracking was analyzed by 
NTA 3.1 software. NTA tracks single particles in Brownian 
motion through the light they scatter. Videos of the particle’s 
tracks, projected on the x–y plane, observed through a 20× 
microscope, were analyzed by the built-in NTA 3.1 software 
that locates and follows the center of each individual particle 
moving in the observation volume, determining the average 
distance moved by each particle in the x and y directions. 
This value is then converted into particle size on the basis of 
a variation of Stokes–Einstein equation taking into account 
that the motion is tracked in two dimensions:
 
( , )x y
Tk
d
2
4
3
= B
h
πη
 
where k
B
 is the Boltzmann constant and ( , )x y 2  is the mean-
squared displacement of a particle during time t at tempera-
ture T, in a medium of viscosity η, with a hydrodynamic 
diameter of d
h
.34
Furthermore, knowing the volume of the suspension and 
the dilution, the associated NTA software is capable of cal-
culating an approximate concentration of the nanoparticles 
inside the colloidal suspension.35
Only SVT-LCN_MaiLab were analyzed by NTA. The 
nanoemulsion was highly diluted (1:630,000) with ultrapure 
water to allow single particle tracking. After that, sample 
was drawn into a 1 mL plastic syringe, which was used for 
full-sample injection into the instrument sample chamber. 
The nanoparticle images were acquired using a video capture 
mode of the sample for three 60-second analyses, which 
were used for subsequent analysis. Measurement was carried 
out at a defined temperature (28°C–28.2°C) and viscosity 
(0.828–0.832 cP). The results were obtained as mean and 
SD of three runs.
Nanoparticle imaging by scanning transmission electron 
microscopy
The morphology of simvastatin raw material, simvastatin-
loaded lecithin/chitosan nanospheres (without oily core), 
blank LCN_MaiLab nanocapsules and SVT-LCN_MaiLab 
nanocapsules, was observed by scanning transmission 
electron microscopy (STEM) using an EVO® electron 
microscope (ZEISS International, Oberkochen, Germany) 
operating at an accelerating voltage of 30 kV. A drop of 
sample solution was placed onto a 200 mesh copper grid 
coated with carbon (Agar Scientific, Stansted, UK) and 
air dried for 1 minute, after which excess solution was 
removed gently with filter paper. Subsequently, a drop of 
2% (w/v) phosphotungstic acid was used as a staining agent 
and removed after 30 seconds. The images were obtained 
via inverse contrast imaging with magnification between 
75,000× and 150,000×.
Determination of nanoparticle structure and interaction 
with a nasal mucus model by saXs
The internal structure of nanoparticles and the structural 
changes occurring upon their interaction with a model of 
nasal mucus were investigated by Synchrotron small-angle 
X-ray scattering (SAXS) technique. Experiments were 
performed at the ID02 high-brilliance beamline (ESRF, 
Grenoble, France). The X-ray beam cross section was 
200×400 µm with λ=0.1 nm. All measurements were per-
formed at T=25°C. Samples were put in plastic capillaries 
(KI-BEAM; ENKI srl, Concesio, Italy) with 2 mm internal 
diameter, mounted horizontally onto a thermostated sample 
holder. The region of investigated momentum transfer, 
q = (4π/λ) sin(θ ), was 0.0116 q 6.43 nm-1, where 2θ is 
the scattering angle. In order to prevent any radiation damage, 
several frames with very short exposure time (0.1 second) 
were acquired, and then checked and averaged. After solvent 
subtraction, the measured SAXS profiles reported the nano-
particles’ scattered radiation intensity as a function of the 
momentum transfer, q. SVT-LCN_MaiLab were prepared 
according to the above-described protocol at a final con-
centration of 7.1 mg/mL. In order to assess the stability of 
SVT-LCN_MaiLab in the presence of artificial mucus and 
their interaction with lysozyme, SAXS analyses were also 
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performed on nanoparticle dispersions in simulated nasal 
fluid (8.77 mg/mL sodium chloride, 2.98 mg/mL potassium 
chloride, and 0.59 mg/mL calcium chloride dihydrate) at 
three different mucus concentrations 2%, 1%, and 0.5% 
(w/v), and the kinetics of interaction in the presence of both 
mucus (0.5%) and lysozyme (0.5 mg/mL) was followed 
within 8 hours.
Quantification of simvastatin in LCNs
The simvastatin content in nanoparticles was measured using 
a high-performance liquid chromatography (HPLC) system. 
The instrumentation consisted of ESA model 542 autosam-
pler (Chelmsford, MA, USA), ESA model 584 pump and 
Shimadzu SPD10A UV detector (Kyoto, Japan). A reverse 
phase C
18
 column (Luna, 250×3.0 mm, 5 µm; Phenomenex, 
Torrance, CA, USA) was employed for chromatographic 
separation of both simvastatin’s isoforms, that is, lactone 
and hydroxy-acid form,36 with a mobile phase consisting of 
a 65:35 (v/v) mixture of acetonitrile and 0.025 M sodium 
dihydrogen phosphate buffer (pH 4.5) at a flow rate of 
0.8 mL/min. The UV detector was set at 238 nm with a sam-
ple injection volume of 50 µL. In order to quantitatively con-
vert simvastatin into its hydroxy-acid form, simvastatin was 
dissolved in ethanol and added to 1.5 volumes of 1 N NaOH 
and heated at 50°C for 2 hours. Next, the pH of the solution 
was adjusted to 7.2 with HCl, and the volume was made up 
with water to 10 mL. Linearity of calibration curves for both 
simvastatin and its hydroxy-acid form was verified in the 
range of 0.5–50 µg/mL (r=0.998 and r=0.999, respectively). 
Limit of detection and limit of quantification were 0.02 and 
0.08 µg/mL for simvastatin and 0.06 and 0.18 µg/mL for 
simvastatin hydroxy-acid form, respectively.
The encapsulation efficiency (EE) of nanoparticles was 
determined by an indirect method; that is, the amount of 
precipitated and free simvastatin were quantified and sub-
tracted from the total amount of the drug quantified in the 
total preparation, and all amounts were determined by HPLC, 
and then expressed as a percentage of the total drug in the 
preparation. The total amount of simvastatin in the formula-
tions was quantified. Firstly, 100 µL of the preparation was 
dispersed in 10 mL of ethanol by sonication for 15 minutes 
(ultrasonic cleaner; VWR, Radnor, PA, USA) to extract the 
entire amount of drug. Then, the ethanol dispersion was 
heated at 60°C in a tightly closed container for 5 minutes to 
solubilize the drug content extracted from the nanoparticles 
and directly assayed for HPLC. For the quantification of 
precipitated and free simvastatin in the aqueous medium, 
colloidal suspensions were first centrifuged at 1,500× g for 
10 minutes (Medifuge; Heraeus Sepatech Gmbh, Hanau, 
Germany) to separate the nanoparticles from any large pre-
cipitate. The pellet obtained for each sample was resuspended 
with ethanol, submitted to a brief sonication process to solubi-
lize the drug and then analyzed by HPLC. An aliquot of 2 mL 
of supernatant obtained in the previous step was further cen-
trifuged using Vivaspin® Centrifugal Concentrator (MWCO 
30,000 Da; Sartorius) at 4,000× g for 10 minutes (Medifuge, 
Heraeus Sepatech Gmbh) to separate the dissolved and hence 
non-encapsulated simvastatin. The ultrafiltered solution was 
diluted with ethanol by the same method used for pellet 
quantification and analyzed by HPLC as well. All analyses 
were performed in triplicate (n=9 ± SD). EE of simvastatin 
was determined by using the following formula:
 
EE%
Total amount of SVT
(PrecipitatedSVT DissolvedSVT)
Total am
=
−
+
ount of SVT
100*
 
In vitro drug release from lcNs
In vitro release from SVT-LCN_MaiLab nanocapsules was 
studied using simulated nasal electrolytic solution (SNES) 
containing potassium, calcium, and sodium at biologic human 
concentrations of the nasal fluid, as described by Castile 
et al.37 In order to obtain sink conditions during the release 
experiments, simvastatin solubility in SNES was increased 
by adding 0.5% (w/v) BSA to the dissolution medium.
The test for in vitro release from SVT-LCN_MaiLab in the 
SNES–0.5% BSA release medium at pH 6.5 was conducted 
using the dialysis bag technique (dialysis tube membrane, 
MWCO 14,000 kDa; Sigma-Aldrich). A volume of 1 mL of 
the nanoemulsion was diluted with 1 mL of SNES at pH 6.5 
and placed in the dialysis bags. The sealed bags were immersed 
into 100 mL of the release medium containing 0.5% BSA kept 
at 37°C and magnetically stirred at 100 rpm. At predetermined 
time points (0, 1, 2, 3, 4, 5, 6, 7, 8, and 24 hours), 1.5 mL ali-
quots of the dissolution medium were taken and replaced with 
an equivalent amount of fresh release medium. Samples were 
analyzed by HPLC to determine the released simvastatin. The 
same experiment was conducted using a 1 mg/mL simvastatin 
suspension in ultrapure water used as control. In vitro release 
studies were replicated three times for both simvastatin nano-
particles and simvastatin suspension.
cytotoxicity assay of sVT-lcNs
Cytotoxicity assays of simvastatin suspension, SVT-LCN_
MaiLab and Blank-LCN_MaiLab were conducted using the 
human nasal septum carcinoma cell line RPMI 2650 (ATCC) 
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and performing an MTT [3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide] cytotoxicity assay. The 
RPMI 2650 cell line was cultured in an MEM containing 10% 
(v/v) FBS and 1% nonessential amino acid solution and incu-
bated at 37°C with 95% air humidity and 5% CO
2
 atmosphere. 
Cells were seeded at an initial density of 50,000 cells per well 
and incubated for 24 hours to allow cell adhesion in 96-well 
cell culture cluster (Costar; Corning Incorporated). Different 
concentrations from 0 to 240 µM of simvastatin nanoparticles, 
SVT-LCN_MaiLab and Blank-LCN_MaiLab were prepared 
by direct dilution in cell culture medium. To prepare the raw 
simvastatin solution, dimethyl sulfoxide (DMSO) was used 
as simvastatin solvent and diluted to low final concentration 
(0.1%) to avoid toxicity effects of the solvent on the cell 
viability. The cells were treated with the formulations for 
72 hours, followed by incubation in MTT reagent for 2 hours 
at 37°C. Next, the cell medium was removed, and 120 µL of 
DMSO was added to each well to dissolve the violet-colored 
metabolite. The plates were shaken for 15 minutes, the 
contents were pipetted and transferred to new plates and the 
absorbance was measured at 570 nm using a microplate reader 
(Spark 10 M; Tecan, Männedorf, Switzerland). Absorbance 
values were considered directly proportional to cell viability, 
and percentage cell viability was calculated by comparison to 
control values obtained for untreated cells.
gamma scintigraphy studies
Particles labeling with 99mTc
A preliminary experiment to evaluate the administration of 
simvastatin-loaded nanoparticles was carried out in rats by 
gamma scintigraphy. SVT-LCN_MaiLab and a simvastatin 
suspension were both labeled with 99mTc based on previous 
experiences, in which anti-CD3 monoclonal antibody was 
successfully labeled.38–40
Briefly, 60 µL of simvastatin nanoparticles or simvastatin 
suspension (1 mg/mL) was incubated with 100 µL of 
SnCl
2
 (0.6, 6, or 60 µg) (Sigma-Aldrich) in 0.9% NaCl for 
20 minutes at room temperature. Afterward, 100 µL (100 µCi) 
of pertechnetate (99mTcO4-; CNEN/IPEN, São Paulo, Brazil) 
was added, and the reaction mixture was incubated for 
further 10 minutes at room temperature. The radiolabel-
ing efficiency of the nanoparticle and the simvastatin was 
evaluated using thin-layer chromatography (TLC), which was 
carried out using Whatman filter paper No 1 and acetone as 
mobile phase. The radioactivity of the strips was quantified 
in a gamma counter (Wizard2; PerkinElmer, Waltham, MA, 
USA). The nanoparticle and the simvastatin were both suc-
cessfully labeled using 6 µg of SnCl
2
 reaching an average 
94% labeling efficiency. To quantify the TLC results, the 
distance traveled by the substance being considered is divided 
by the total distance traveled by the mobile phase. This is 
called the retention factor (Rf); in this experiment, free 99mTc 
pertechnetate had a high Rf being transported with the mobile 
phase. When the particle labeling was carried out, the new 
radiopharmaceutical conjugate was not efficiently eluted by 
the mobile phase; that is, Rf =0. Efficient radiolabeling was 
considered for a signal at Rf =0%80%.
In vivo biodistribution study
All animal experiments were approved by the Ethics in 
Research Committee of University Hospital Clementino 
Fraga Filho (affiliated university Federal University of Rio de 
Janeiro, Rio de Janeiro, Brazil; [CECA/CCS/UFRJ 129/14]). 
All animals were handled in accordance with Brazilian 
guidelines for the care and use of animals for scientific and 
educational purposes (Conselho Nacional de Controle de 
Experimentação Animal – CONCEA, 2016). Nine Wistar 
rats weighing 300–350 g obtained from the central vivarium 
were used. The animals had free access to a standard rat diet 
and tap water at all times during the studies. Three Wistar rats 
per group were placed individually in an induction chamber, 
and anesthesia was induced with 1% isoflurane. Then, 10 µL 
of the radiolabeled formulation, that is, SVT-LCN_MaiLab, 
simvastatin suspension or a simple pertechnetate solution 
(TcO4-), was instilled with a micropipette in each nostril of 
the animal. Ninety minutes post-administration, the animals 
were sacrificed with a high dose of isoflurane (5%), and the 
organs were collected for biodistribution analysis.
For quantitative biodistribution analysis, the brain, 
heart, lungs, liver, kidneys, spleen, and stomach of rats were 
removed and weighed. The total radioactivity administered 
to each animal and the radioactivity present in each organ 
were measured in a gamma counter (Packard Cobra II Auto-
Gamma Counter; PerkinElmer). The percentage of the dose 
per gram of the organ (% gram/tissue: % dose/organ/mass 
in grams) was determined for each sample.
statistics
All results were reported as mean and SD of at least three 
replicates, unless stated otherwise. Cytotoxicity IC
50
 values 
were calculated by using a nonlinear (sigmoidal, 4PL) fitting 
of each data set (Prism, Version 7.0a; GraphPad Software 
Inc., La Jolla, CA, USA). The differences between data were 
tested using Student’s t-test (paired, two-tailed) consider-
ing significant differences with P0.05. The results of the 
biodistribution assays were analyzed using two-way analysis 
of variance, and a Tukey’s multiple comparisons test was 
used to compare the groups. Differences were considered to 
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be statistically significant at P0.001 (Prism, Version 7.0a; 
GraphPad Software Inc.).
Results
Preparation and physicochemical 
characterization of sVT-lcNs
Simvastatin nanoparticles were formed via the electrostatic 
self-assembly of lecithin and chitosan. In previous papers, 
this system was shown to be adapted for the encapsulation 
of lipophilic drugs, but the loading efficiency was limited 
by the affinity of the drug for the phospholipid component 
of the nanosystem.31,41
In this study, in order to improve their loading capacity, 
nanoparticles were produced by adding to the formulation 
different oils on the basis of literature solubility studies of 
simvastatin. Maisine, Labrafac, Capryol PGMC, and Capryol 
90 were chosen, and formulated with lecithin/chitosan in 
binary combinations, at the maximum amount compatible 
with the production of stable nanoparticles. Preliminary 
experiments were carried out to determine the maximum 
amount of oils that could be used to produce stable nano-
particles (data not shown).
To select the optimal formulation, all nanoparticles 
prepared were characterized for size, PDI, zeta potential, 
drug-loading efficiency, and stability during 3-month storage 
at room temperature. Table 1 reports the average size, PDI, 
zeta potential, and drug-loading efficiency of SVT-LCNs 
produced without oil and with different oil combinations.
SVT-LCNs produced without oily excipients showed 
higher average size (around 270 nm) and smaller positive 
surface charge compared to blank nanoparticles (LCNs). 
Furthermore, substantial precipitation of simvastatin affected 
the EE of SVT-LCN. The EE was approximately 22%. 
In all the examined cases, the addition of oil significantly 
reduced the amount of drug precipitated during preparation of 
nanoparticles. This was consistent with an improved loading 
capacity provided by adding an oily core to nanoparticles, 
leading to a fourfold increase in EE. In preliminary studies 
carried out with only Maisine, it was observed that the EE of 
simvastatin was increasing with increasing oil concentration 
(Table 1 presents the data for LCN_Mai and LCN_Mai
2
). 
It was hypothesized that the combination of different types 
of oils could promote a further improvement in EE. In most 
cases, no significant improvement was obtained. It can be 
seen in Table 1 that the addition of the oil combinations 
Cap
I
Cap
II
 and LabCap
I
 in formulations (SVT-LCN_Cap
I
Cap
II
 
and SVT-LCN_LabCap
I
) did not result in a significant 
variation in the average size compared to SVT-LCNs or 
EE when compared to lecithin/chitosan Maisine-containing 
nanoparticles (SVT-LCN_Mai
2
). On the other hand, SVT-
LCN_MaiCap
I
 showed larger particle size (352 nm) but not a 
dramatic increase in loading capacity. All the oil-containing 
formulations evidenced a positive surface charge with 
values ranging from +11 to +48 mV. The preparations with 
higher particle sizes also showed reduced surface charge 
and higher PDI, with a potential negative effect on their 
long-term stability. In fact, SVT-LCN_Cap
I
Cap
II
 and SVT-
LCN_MaiCap
I
 preparations evidenced precipitation or floc-
culation just few days after preparation. SVT-LCN_LabCap
I
 
was apparently stable over 1-month storage but displayed a 
slight phase separation over longer times.
On the other hand, the addition of the oil combination 
Maisine and Labrafac had a huge positive effect. In fact, 
simvastatin-loaded nanoparticles produced using Maisine 
and Labrafac (SVT-LCN_MaiLab) showed a significantly 
smaller particle size (204 nm), elevated positive surface 
charge (nearly 50 mV) and high drug-loading efficiency, 
encapsulating 98% of the total amount of simvastatin. More-
over, SVT-LCN_MaiLab were found to be monodispersed 
(PDI 0.1). In addition, the system remained chemically 
and physically stable at room temperature up to 3 months, 
as shown in Table 2. Therefore, the SVT-LCN_MaiLab 
Table 1 Physicochemical properties and ee of simvastatin-loaded nanoparticles (n=9± sD)
Formulation Oil ratio Particle size (nm) Zeta potential (mV) PDI EE (%)
lcN – 146.7±26.2 +57.26±2.57 0.380±0.025 –
sVT-lcN – 272.0±12.6 +34.43±2.13 0.263±0.040 22.60±20.80
sVT-lcN_Mai 1:0 192.4±22.5 +36.63±2.25 0.120±0.035 74.13±6.04
sVT-lcN_Mai2 2:0 184.9±9.5 +45.30±1.08 0.089±0.004 86.90±6.28
lcN_Mailab 1:1 205.6±10.2 +50.20±2.17 0.129±0.017 –
sVT-lcN_Mailab 1:1 204.5±15.4 +48.45±4.09 0.098±0.040 98.52±1.33
sVT-lcN_capIcapII 1:1 280.4±9.2 +20.17±2.03 0.185±0.045 88.78±0.99
sVT-lcN_MaicapI 1:1 352.0±33.9 +11.34±3.21 0.223±0.020 90.74±0.87
sVT-lcN_labcapI 1:1 271.1±8.1 +17.01±2.98 0.154±0.040 94.68±0.65
Note: ‘–’ indicates no data.
Abbreviations: EE, encapsulation efficiency; SD, standard deviation; PDI, polydispersity index; LCN, lecithin/chitosan nanoparticle; SVT-LCN, simvastatin-loaded lecithin/
chitosan nanoparticle; Mai, Maisine; Mai2, double Maisine; lab, labrafac; capI, propylene glycol monocaprylate type I; capII, propylene glycol monocaprylate type II.
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formulation was selected for further experiments, as it 
presented small and narrow particle size distribution, posi-
tive and sufficiently high superficial charge and optimal drug 
entrapment efficiency.
Nanoparticle tracking analysis
In order to confirm the particle-sizing data obtained by 
DLS, SVT-LCN_MaiLab particle size distribution and con-
centration were measured using NTA. NTA is a relatively 
new investigation technique that offers direct and real-time 
visualization, sizing, and counting of nanoparticles, allowing 
high-resolution particle size distributions to be obtained.42 
Results are shown in Figure 1. The particle size distribution 
showed a peak at 101.0±4.6 nm with 90% of the particles 
being 132.1±13.0 nm, confirming the narrow size distri-
bution of the nanoparticles. A smaller NTA average particle 
size in comparison with DLS results was expected due to the 
different weighting functions and the intensity scattered by 
particles for DLS which is much larger for large particles. 
NTA provides complementary information to both DLS 
and microscopy. In fact, as it follows individual particles, 
it enhances the resolution of polydispersed particle population 
which is usually obtained by DLS. The technique still operates 
on a statistically significant number of particles, larger than for 
microscopy, although not determining their morphology.43
NTA measurements also confirmed the stability of the 
lecithin/chitosan oil core nanoparticles prepared using Maisine 
and Labrafac combination, as similar results were obtained for 
the same formulation stored for 3 months at room temperature 
(data not shown).
Nanoparticles imaging by sTeM
LCNs were further characterized by STEM (Figure 2). 
Simvastatin raw material, SVT-LCNs and SVT-LCNs pre-
pared using Maisine and Labrafac (SVT-LCN_MaiLab) are 
shown in Figure 2A–C, respectively. Simvastatin suspension 
was organized as agglomerates of individual elongated crystals 
of few micrometers in size (Figure 2A). LCNs prepared with-
out oil loaded with simvastatin produced spherical spongy 
particles in the range of 100–500 nm, as shown in Figure 2B. 
Large simvastatin crystals were also observed within this 
formulation, as a consequence of low encapsulation efficacy, 
and consistently showed extensive precipitation during nano-
particle preparation. The incorporation of oils, that is, Maisine 
Table 2 Physical and chemical stability study at room temperature of simvastatin-loaded nanoparticles (sVT-lcN_Mailab)
Storage time (months) Particle size (nm) Zeta potential (mV) PDI EE (%)
0 204.5±15.4 48.4±4.1 0.098±0.040 98.52±1.33
1 205.5±15.2 48.1±3.2 0.166±0.024 97.11±1.25
3 201.9±18.6 40.0±2.5 0.131±0.033 96.54±1.13
Abbreviations: PDI, polydispersity index; EE, encapsulation efficiency; SVT-LCN, simvastatin-loaded lecithin/chitosan nanoparticle; Mai, Maisine; Lab, Labrafac.
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Figure 1 Particle size distribution vs nanoparticles concentration and intensity of scattered light obtained by NTa. 
Notes: Particle size distribution is expressed as average and standard error of the mean of nanoparticle concentration (n=5) (A). Different colors and sizes of markers 
represent measures of particle size and scattered light intensity of single particles from the five independent experiments (B).
Abbreviation: NTa, nanoparticles tracking analysis.
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and Labrafac, into the formulation of the LCNs significantly 
improved the nanoparticle morphology and size distribution. 
SVT-LCN_MaiLab (Figure 2C) appeared as small almost 
perfectly spherical nanoparticles with narrow size distribution 
(150–250 nm). Additionally, the increased EE of simvastatin 
following incorporation of oils into the formulation was con-
firmed by the absence of large simvastatin crystals.
Nanoparticles structure and interaction 
with the nasal mucus model
To investigate the internal structure of nanoparticles, SAXS 
measurements were performed on blank and simvastatin-loaded 
nanoparticles. In Figure 3, we report the scattered X-ray intensity 
profiles for LCN, LCN_MaiLab, and SVT-LCN_MaiLab.
Spectra were very different all over the investigated q 
region. Blank LCNs (bottom black line in Figure 3) showed 
the characteristic features of closed lamellar structures, such 
as vesicles, with low multilamellar layering as evidenced 
previously.30 The structure peak at q =1.13 nm-1 corresponded 
to a characteristic interlamellar distance of 5.6 nm. In fact, the 
momentum transfer q was related to the characteristic scatter-
ing distance of supramolecular structures d by the equation:
 
d
q
= 2π
 
The obtained bilayer contrast profile is reported in the 
insert of Figure 3 (bottom black profile). The structural 
parameters were in agreement with typical values for 
lipid/polysaccharide nanoparticles:30 the overall size was 
140±20 nm, and the hollow water core was surrounded by 
one or more lipid bilayers, each 5 nm thick, with the interlayer 
regions containing water and chitosan.
Intensity spectra of LCN systems containing Maisine and 
Labrafac oils (LCN_MaiLab, blue line in Figure 3) clearly 
revealed the presence of an oil core that definitely changed the 
P
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%
QP
&
Figure 2 sTeM images of simvastatin crystals (A), sVT-lcNs (B), and sVT-lcN_Mailab (C).
Abbreviations: STEM, scanning transmission electron microscopy; SVT-LCNs, simvastatin-loaded lecithin/chitosan nanoparticles; Mai, Maisine; Lab, Labrafac.
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Figure 3 saXs intensity spectra of lcN (black line), lcN_Mailab (blue line), and 
sVT-lcN_Mailab (red line). 
Notes: The corresponding electron density profiles (e/Å3) across the bilayer are 
shown in the insert. IN is the core region, and OUT is the bulk solvent region and 
z is the distance from the center of the bilayer. (e/Å3) is the electron density for 
number of electrons/ volume.
Abbreviations: SAXS, small-angle X-ray scattering; LCNs, lecithin/chitosan nano-
particles; Mai, Maisine; lab, labrafac; q, momentum transfer.
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contrast of the inner region, the “IN” electron density being 
lower than the “OUT” (insert of Figure 3, central blue profile). 
The intensity decay in the low-q region was proportional to 
q-4, as expected for globular particles with well-defined inter-
faces. The overall size of oil-containing particles was roughly 
200 nm. The nanoparticle structure was core–shell type: the 
oil core was surrounded by a multilayer shell, as visible in the 
high-q region of the spectra. The obtained profile of bilayers 
belonging to the shell showed that their structure was affected 
by the presence of the oil component, as reported in Figure 3. 
The internal hydrophobic region of the lamellae was thicker 
than for blank nanoparticles. Accordingly, the interlamellar 
peak appeared at lower q values (1 nm-1) corresponding to 
a characteristic distance of 6.3 nm, larger than for oil-free 
nanoparticles. Simvastatin-loaded nanoparticles (SVT-LCN_
MaiLab) showed a structure quite similar to the unloaded ones. 
Interestingly, simvastatin seemed not only to be embedded in 
the oil core, but also in the shell structure, lowering its electron 
density as compared to the unloaded nanoparticles.
To investigate the structural changes induced by the interac-
tion of the nanoparticles with mucus, SAXS analyses were also 
performed on SVT-LCN_MaiLab dispersions in the presence 
of artificial mucus in simulated nasal fluid (2%, 1%, 0.5% 
[w/v]). Figure 4, left panel, reports the intensity spectrum of the 
nanoparticles in 0.5% artificial mucus together with that of the 
mucus itself. In the right panel, the spectrum obtained originally 
for the nanoparticles in simulated nasal fluid is compared to the 
one of the nanoparticles inside the mucus, after subtraction of 
the mucus contribution to the scattered intensity.
First, it was observed that in the presence of mucus, 
nanoparticles were still detected and kept the same core–shell 
structure. Differences were visible in the high-q region of the 
spectra, corresponding to the local scale. The characteristic 
structure peak shifted to q =0.89 nm-1, corresponding to an 
interlamellar distance of 7 nm. The adjacent bilayers swelled, 
as indicated by the increased thickness of the interlamellar 
solvent layer, showing that the particle was stretched by the 
presence of the mucus matrix. Meanwhile, the intensity of 
the structure peak was decreased, suggesting a peeling off of 
layers from the multilayer shell. Moreover, an additional small 
peak at q =0.38 nm-1 stemmed for polymer (chitosan and/or 
mucin) coordination, with a correlation length of ~16.5 nm.
Finally, the effect and kinetics of the interaction upon 
addition of lysozyme to the mucus/nanoparticles system were 
tested, following its structural evolution over several hours. 
Lysozyme is a protein widely present in natural mucosal secre-
tions, being one of the most abundant antimicrobial factors 
that constitute the innate immunity.44 Lysozyme at a physi-
ological concentration (0.5 mg/mL)45 was added in mucus plus 
SVT-LCN_MaiLab dispersion, and subsequent SAXS spectra 
were acquired at different incubation times. The correspond-
ing intensity spectra are reported in Figure 5. Experimental 
results revealed that lysozyme interacts with nanoparticles 
helping the peeling process of the multilayer shell. In fact, 
both the characteristic structure peaks were moving to lower q 
values, and the associated intensity decreased. After 6 hours, 
the effect was almost complete. In the first hours, the external 
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Figure 4 SAXS intensity spectra of SVT-LCN_MaiLab dispersed in artificial mucus. 
Notes: Left panel: SVT-LCN_MaiLab in 0.5% artificial mucus (black line) and 0.5% 
mucus (gray line). Right panel: SVT-LCN_MaiLab before interaction with artificial 
mucus (red line) and in mucus, after mucus spectrum subtraction (green line).
Abbreviations: saXs, small-angle X-ray scattering; q, momentum transfer; sVT-
LCNs, simvastatin-loaded lecithin/chitosan nanoparticles; Mai, Maisine; Lab, Labrafac.
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Figure 5 sVT-lcN_Mailab interaction with mucus plus lysozyme.
Notes: SAXS intensity spectra of SVT-LCN_MaiLab in artificial mucus (0.5%) after 
mucus subtraction: without lysozyme (green line) and in interaction with lysozyme 
at different times: t=0 hours (orange line), t=6 hours (pink line), and t=8 hours 
(violet line). The arrow indicates the position of the characteristic structure peak 
of nanoparticles.
Abbreviations: saXs, small-angle X-ray scattering; sVT-lcNs, simvastatin-loaded 
lecithin/chitosan nanoparticles; Mai, Maisine; Lab, Labrafac; q, momentum transfer.
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layers of the shell progressively swelled and peeled off sug-
gesting a specific biodegradation of the nanoparticles as a 
consequence of the interaction with the enzyme.
simvastatin release studies
In vitro release testing is an important analytical tool, used 
to investigate and establish product behavior and stability 
during each step of the drug development.46 The in vitro drug 
release was measured via the dialysis bag diffusion method 
which is one of the most commonly used dissolution methods 
for the testing of nanoformulations designed for nasal drug 
delivery.47–49 SVT-LCN_MaiLab were chosen for testing due 
to their optimal EE of drug and suitable physicochemical 
features, and a suspension of simvastatin was used as control. 
The simvastatin release profile from SVT-LCN_MaiLab 
can be seen in Figure 6. A simulated nasal fluid at pH 6.5, 
containing sodium, potassium, and calcium salts, was used 
to simulate the nasal conditions. Due to the low solubility of 
simvastatin in aqueous solution, BSA was used to increase 
simvastatin solubility in the dissolution medium outside the 
dialysis bag to achieve sink conditions throughout the experi-
ment. BSA was selected for being closer to physiological 
conditions in comparison to surfactants or co-solvents gener-
ally used to increase the solubility of poorly soluble drugs. 
The in vitro release tests were performed over 24 hours for 
SVT-LCN_MaiLab and simvastatin suspension. For the sus-
pension, after an initial rapid release in the first hour, a plateau 
characterized by a very low dissolution rate was reached. This 
was not observed for the nanoparticle formulation. In fact, the 
nanoparticles kept releasing simvastatin at a constant release 
rate from the second hour to the end of the experiment. As 
shown in Figure 6, 40% of simvastatin was released from 
SVT-LCN_MaiLab within 8 hours and 50% in 24 hours, 
displaying a significantly faster release than the simvastatin 
suspension (21.17% simvastatin released after 8 hours by 
the suspension).
cytotoxicity studies
In the last few years, the human RPMI 2650 epidermoid 
carcinoma cells have been proposed as a suitable model 
of nasal mucosa for in vitro studies simulating nasal drug 
transport.50 Recently, this nasal epithelial cell line has been 
grown in air–liquid interface conditions to develop an in vitro 
model of the nasal mucosa suitable for studies of deposition 
and permeation of nasally administered formulations. These 
cells also appear a good choice for in vitro cytotoxicity assay 
of a new formulation such as SVT-LCNs. For this purpose, 
RPMI 2650 cells were incubated for 72 hours with increasing 
concentrations of simvastatin solution, blank nanoparticles, 
and simvastatin-loaded nanoparticles. The cells viability was 
recorded as percentage in comparison to untreated cells and 
plotted in Figure 7 against the simvastatin concentration. In 
the case of blank nanoparticles, this value corresponded to 
the equivalent amount of carrier nanoparticles.
Blank particles did not show any cytotoxicity indicating 
that the carrier is suitable for nasal administration. Results 
showed that cells viability also remained around 100% in the 
highest concentration, suggesting that our LCNs containing 
oil are highly biocompatible.
Cytotoxicity of simvastatin and SVT-LCN_MaiLab 
appeared to be dose-dependent, as seen through the cells viabil-
ity. For SVT-LCN_MaiLab, IC
50
 was found to be 9.92 µM, 
which was nearly three times that of pure simvastatin (3.50 µM), 
and displayed a reduced toxicity compared to the pure drug.
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Figure 6 Simvastatin release profile from SVT-LCN_MaiLab (filled circle) and a 
control simvastatin suspension (open circle) in simulated nasal fluid with 0.5% BSA 
at ph 6.5 and 37°c.
Abbreviations: BSA, bovine serum albumin; SVT-LCNs, simvastatin-loaded lecithin/ 
chitosan nanoparticles; Mai, Maisine; lab, labrafac.
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Figure 7 In vitro cytotoxicity studies on human nasal cell line rPMI 2650 of 
simvastatin (filled triangle), simvastatin-loaded nanoparticles (SVT-LCN_MaiLab, 
filled circle), and blank nanoparticles (LCN_MaiLab, open circle).
Notes: cell viability is plotted against the logarithm of simvastatin concentration.
Abbreviations: SVT-LCNs, simvastatin-loaded lecithin/chitosan nanoparticles; Mai, 
Maisine; lab, labrafac.
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gamma scintigraphy studies
A preliminary study of biodistribution in rats after nasal 
administration of 99mTc-labeled nanoparticles was carried out 
by gamma scintigraphy which was compared to the admin-
istration of a radiolabeled suspension of simvastatin and 
pertechnetate solution alone, used as controls. Figure 8 shows 
organ distribution of the radioactivity detected 90 minutes 
after the nasal instillation in each nostril of 10 µL nanopar-
ticles or drug suspension. The radioactivity distributions 
were very different. In the case of the drug suspension, most 
of the radioactivity was found in the lung, followed by far 
by the stomach and the liver. Only a very limited amount of 
radioactivity was found in other organs or in the brain. In the 
case of the pertechnetate solution, radioactivity was mainly 
found in the stomach. On the contrary, after the nasal admin-
istration of nanoparticle formulation, a significant fraction of 
the radioactivity (more than 20%) was localized in the brain, 
followed by an accumulation in the kidneys comparable to the 
levels observed for controls. Other organs such as the liver, 
lung, heart, and stomach contained progressively decreasing 
amounts of radioactivity.
Discussion
Administration of poorly soluble drugs intranasally for 
systemic and CNS therapeutic action can be extremely chal-
lenging due to the low volume of nasal secretions, the barrier 
provided by the mucus layer and the short time available for 
dissolution/absorption because of mucociliary clearance.51,52
It is considered that nanoparticles could improve the bio-
availability of nasally administered substances.53,54 Chitosan 
and lecithin have been used to produce nanoparticles and 
liposomes for many years.55–57 The main advantages attrib-
uted to these components are their biocompatibility and 
biodegradability, and in fact, liposomes are still by far the 
most successful nanomedicines on the market.58 Recently, 
our research group proposed hybrid nanoparticles formed by 
the electrostatic interaction of these two components, that is, 
the positively charged polysaccharide chitosan and the nega-
tively charged phospholipids of soybean lecithin.59,60 These 
nanoparticles were demonstrated to be extremely effective 
in the improvement of accumulation of corticosteroid drugs 
in skin layers and of the permeation of tamoxifen through 
the intestinal epithelium.31,61,62
As a consequence, it has been hypothesized that this 
delivery system could be an interesting candidate for the 
nasal administration of lipophilic drugs, in particular for 
the nose-to-brain pathway. Simvastatin was selected as 
an ideal model drug as it has a sound rationale for its use 
in neurodegenerative diseases and could benefit from an 
alternative administration route, providing a direct access 
to the CNS.63
In order to efficiently load simvastatin into LCNs, it was 
necessary to add into the formulation an oily component. 
Various pharmaceutical lipophilic solvents were selected 
based on simvastatin solubility data reported in the literature. 
In a systematic study of simvastatin solubility in oils and 
surfactants, Capryol PGMC and Capryol 90 were found to 
be the best solvents for simvastatin (~105 mg/mL), followed 
by other oily excipients, such as Maisine (~60 mg/mL) and 
Labrafac (~25 mg/mL).64 Therefore, combinations of these 
oils were used in order to optimize EE of simvastatin in 
LCNs. Nanoparticles with a positive surface charge and a 
size of around 200–300 nm in size were obtained, showing 
a good EE of simvastatin and providing a 30-fold increase 
in simvastatin apparent solubility in water. Interestingly, the 
best formulation, containing the combination of glyceryl 
monolinoleate (Maisine) and medium-chain triglycerides 
(Labrafac), reached an apparent simvastatin solubility which 
is fivefold of that expected by extrapolating from the solubil-
ity of the drug in the two solvents and from their respective 
amounts in the formulation, showing a synergistic effect. This 
suggests an optimized accommodation of the simvastatin into 
the oily core of the particles surrounded by a lecithin/chitosan 
shell, as evidenced by the SAXS experiments. It could be 
hypothesized that Maisine, a lipid with a slightly higher melt-
ing point than the others selected (Maisine is liquid at 40°C), 
 
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Figure 8 radioactivity biodistribution in Wistar rats 90 minutes after the nasal 
instillation of 20 µl (10 µl in each nostril) of 99mTc-labeled simvastatin-loaded 
nanoparticles, simvastatin suspension, and pertechnetate (TcO4-) expressed as 
percentage of administered dose (%D) per gram of tissue (n=3, *P0.001).
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can intimately mix with the molecules of Labrafac when 
heated, forming a semisolid oil core when cooled down at 
room temperature, favoring simvastatin entrapment. In fact, 
LCN_MaiLab showed the highest EE of formulated drug, 
encapsulating it almost entirely.
Concerning the stability of the preparations, it has been 
previously reported that surface charge is an important indi-
cator of the stability of nanoparticles. In particular, when the 
zeta potential exceeds 30 mV, nanoparticles are regarded 
as stable, their stability increasing along with net surface 
charge.65 Blank nanoparticles displayed similar values of 
zeta potential, generally higher than their equivalent loaded 
nanoparticles (Table 1). The surface charge of all LCNs was 
highly positive, as expected due to the presence of chitosan, a 
positive polysaccharide covering the surface of the nanopar-
ticles, as reported previously. The introduction of simvastatin 
and of some oils into LCNs resulted in a decrease in their 
surface charge (SVT-LCN_Cap
I
Cap
II
, SVT-LCN_MaiCap
I
, 
and SVT-LCN_LabCap
I
). As the simvastatin hydroxy-acid 
form is capable of deprotonating to a negatively charged ion, 
this could lead to charge neutralization and loading close to 
the external shell.
On the contrary, the addition of the oil combination 
Maisine plus Labrafac into LCNs (SVT-LCN_MaiLab) did 
not result in an important reduction of the positive surface 
charge, in line with the already suggested efficient trapping 
of simvastatin in a solid lipid core. A similar behavior was 
also observed for SVT-LCN_Mai
2
, supporting the effective-
ness of this oil in embedding simvastatin inside the core, thus 
conferring great stability to the nanoparticles system.
This core–shell organization evidenced from the nano-
particle structure investigation by SAXS is maintained upon 
interaction with mucus. The interaction of the superficial shell 
with the mucus is in agreement with a number of previous 
studies that indicate mucoadhesion as an important feature 
of nasal preparations. In particular, this may provide a much 
higher residence time in the nasal cavity, pivotal to allow an 
enhancement of drug availability.66
For the in vitro release studies, a simulated nasal elec-
trolyte solution containing BSA was preferred to surfactant 
solutions48 or mixtures with organic solvents miscible with 
water67, as a physiological dissolution medium. Generally, 
drug inclusion in nanoparticles is a strategy to prolong the 
release. In this study, on the contrary, after a similar initial 
“burst” release, a faster release rate was evidenced for nano-
particles in comparison to a simple simvastatin suspension, 
likely resulting from the high surface area of nanoparticles and 
the efficient dispersion of the drug in the nanoparticle core. 
This result is even more relevant as usually, apparent drug 
release in dialysis methods is hindered by the dialysis mem-
brane itself, which poses an additional barrier to the diffusion 
of the drug to the receiver compartment.68
As already pointed out, the major drawback affecting 
the nasal administration is the removal of the formulation 
through the mucociliary clearance, a mechanism that can 
reduce the bioavailability of poorly water-soluble drugs.52 
Hence, fast absorption is required in order to achieve the 
needed therapeutic concentrations. The role of chitosan in 
promoting mucoadhesion and penetration is well known. 
Several studies suggest that chitosan nanoparticles are trans-
ported by transmucosal route with increased uptake when 
compared to other nanoparticles as a result of the chitosan 
mucoadhesivity.69,70 However, it is doubtful that slow-release 
nanoparticles would provide a significant improvement of 
intranasal drug delivery.71 For this reason, the present system, 
which is both mucoadhesive and fast releasing as compared 
to a typical formulation for nasal administration of drug 
suspensions, could overcome limitation on delivery due 
to clearance. Moreover, previous studies have shown that 
LCNs are highly susceptible to degradation by GI enzymes, 
thus promoting drug release and drug permeation through 
intestinal epithelium via an enhanced paracellular transport.31 
This degradation is also likely to occur on the nasal mucosal 
surface. Degradation has been evidenced in the presence of 
mucus and lysozyme, where a breakdown of the original 
particle structure occurs over time (Figure 5). In fact, nasal 
secretions are rich in antibacterial peptides and proteins that 
are part of the innate immune defenses of the body.44 Among 
these proteins, one of the most abundant is lysozyme, an 
enzyme able to degrade proteoglycans of bacterial cell wall, 
but also able to degrade chitosan.72 The degradation of the 
nanoparticles by endogenous enzymatic process constitutes 
a new approach for nasal delivery and could represent an 
interesting Trojan-horse strategy for improving the nasal 
bioavailability of statins and other poorly soluble drugs.
Interestingly, despite reports of concerns in the literature 
regarding the biocompatibility of positively charged chitosan 
nanoparticles, the cytotoxicity studies carried out evidenced 
no apparent toxicity of the proposed drug nanocarriers. This 
is of course an important result, as safety is a prerequisite 
to the use of the formulation. In fact, the nasal epithelial 
layer represents one of the first body’s defense lines, and 
materials harming the mucosal barrier constitute a potential 
health risk.73
The cytotoxicity evidenced by simvastatin-loaded nano-
particles is actually related to the statin itself. In fact, several 
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recent studies have demonstrated the anticancer activity of 
statins in various cancer cells.10,74,75 Since RPMI 2650 cells 
are derived from an epidermoid carcinoma of the nasal 
septum, the cytotoxic activity detected is to be attributed to 
the drug released by nanoparticles or by the direct uptake 
of nanoparticles by the cells. As nanoparticles degradation 
and/or drug release is time dependent, SVT-LCN_MaiLab 
showed lower IC
50
 values than simvastatin.
In vivo preliminary studies were carried out to assess the 
potential of the formulation for the proposed nose-to-brain 
delivery of statins. Gamma scintigraphy was selected as a 
powerful and rapid method to evaluate the biodistribution 
of the formulation after nasal administration in rodents.76 A 
suspension of simvastatin was used as a control. It is worth 
pointing out that the radioactivity that is detected cannot 
be considered permanently bound to the particles or to the 
drug molecule. However, it appears clear that after the nasal 
instillation of the nanoparticle formulation, the radioactiv-
ity was localized mainly in the kidneys and in the brain. 
This biodistribution implies a significant absorption of the 
radiolabel through the nasal mucosa, which accounts for 
the localization in the kidney where the radioisotope will be 
eliminated by filtration and an efficient transfer via the nose-
to-brain pathway of around 20% of the administered radio-
activity dose. This was not observed for the controls, that is, 
simvastatin suspension and the solution of the radioisotope 
itself, where the radioactivity mainly localized in the lungs 
and GI tract of the animals, as often happens for rodents 
that are obligate nose breather. It can be hypothesized that 
the nanoparticle formulation is more effective through both 
chitosan-mediated mucoadhesion77 and penetration enhance-
ment via tight-junction opening,78 but also most likely as a 
consequence of mucosal biodegradation of the nanoparticle 
structure. Overall, these processes are able to favor the 
transmucosal absorption of the radioactivity, independently 
from the form it may assume: isotopes linked to entire nano-
particles, particle fragments, polysaccharide chains or free 
from linkage to any of nanoparticle structures.
Conclusion
Although some brain-targeted nanoparticles loaded with 
statins have been proposed by some other authors, this is 
to our knowledge the first research proposing nanoparticles 
to be administered nasally to deliver statins to the brain. 
The particles were designed to optimize the loading of a 
lipophilic drug such as simvastatin and to provide multiple 
features helpful for nasal delivery, such as physical and 
chemical stability, biocompatibility, mucoadhesion, and a 
rapid drug release. Furthermore, the nanoparticles appear 
to be prone to a mucus-specific biodegradation process that 
represents an innovative Trojan-horse strategy able to boost 
the permeation of the encapsulated drug. Preliminary in vivo 
gamma scintigraphy studies showed an enhanced nose-to-
brain transport of the radioactivity administered nasally for 
the SVT-LCNs but not for a more traditional formulation 
such as a suspension. Although further studies are necessary 
to elucidate if the nanoparticles are taken up by the nasal 
epithelium or simply favor the drug absorption without cross-
ing the mucosa and to investigate the pharmacokinetics and 
efficacy of the nanoformulated statin after administration 
via the nasal route, the proposed nanoformulation appears 
to be an optimal drug delivery platform for poorly soluble 
drugs that need to get administered to the nasal mucosa for 
systemic or CNS delivery.
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